Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q3 2025 · 10-Q
Revenue$0.00$0.00— vs Q3 2024 Net Income-$45.50M-$45.50MN/M vs Q3 2024 EPS Diluted-$0.87-$0.87N/M vs Q3 2024 Operating Income-$21,210,455N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$21,641,446N/M ended Sep 30, 2025 · filed Nov 10, 2025 · 41 d after period end